Renal Cell Carcinoma
Advertisement
The FDA has accepted for priority review the sNDA for belzutifan in patients who were previously treated for advanced RCC.
Black patients had a lower survival rate compared with White patients, and they experienced a sharp decline in survival.
Improved PFS was associated with negative surgical margins and no 30-day surgical complications, plus pathologic downstaging.
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
While nephrectomy is a common treatment for kidney cancer, it can result in loss of kidney function or kidney failure.
Belzutifan improves PFS in adult patients with advanced RCC who have progressed on previous PD-1/PD-L1 or VEGF-TKI therapies.
As one of the most aggressive forms of kidney cancer, there is a need for new treatment strategies for RMC.
The EVEREST trial analyzed the effectiveness of everolimus in patients with RCC who have undergone full surgical resection.
Researchers investigated the impact of duration of exposure to antiangiogenics on immunotherapy outcomes in metastatic ccRCC.
Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03.
Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data.
Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates.
Researchers from the Mayo Clinic assessed the efficacy of ICI combination therapy as a first-line mRCC treatment.
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Researchers summarized the survival outcomes of patients with mRCC treated with CN after IO-based perioperative treatments.
Research presented at KCRS23 characterized patients with an OR in the lenvatinib plus pembrolizumab arm of the CLEAR study.
At KCRS23, researchers presented their data on the differences in clinical outcomes in patients with synchronous and metachro
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.